FibroGen Stock News

\- Strong Second Quarter China Roxadustat Net Sales of $15.7 million - \- Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Fibr

\- Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) - \- Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Departme

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) ABIOMED, Inc. (NASDAQ: ABMD) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...

FibroGen (NASDAQ:FGEN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday, Zacks.com reports. According to Zacks, “FibroGen, Inc

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

If you want to know who really controls FibroGen, Inc. (NASDAQ:FGEN), then you'll have to look at the makeup of its...

SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin

Engineers Gate Manager LP purchased a new stake in FibroGen Inc (NASDAQ:FGEN) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (

Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas.

Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside

FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.